Abraxane (paclitaxel protein-bound particles; albumin-bound)
Drug company: Celgene
Abraxane is a microtubule inhibitor used, in combination with Gemzar, for the treatment of patients with advanced or metastatic pancreatic cancer as first-line treatment.
Celgene offers 3 financial assistance programs for patients using Abraxane:
Celgene Commercial Co-pay Program
This program reduces the prescription copay for Abraxane to $25 or less, for patients with private insurance and an annual household income of up to $100,000.
Celgene Patient Assistance Program
Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria may receive Abraxane for free.
Celgene Patient Support
The program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.
Drug company: Eli Lilly
Gemzar is a nucleoside metabolic inhibitor used to slow down the growth of cancer cells in patients with stage II or stage III pancreatic cancer where the tumor cannot be removed, and in patients with stage IV metastatic pancreatic cancer.
Lilly PatientOne offers 1 financial assistance program for patients using Gemzar:
Lilly Cares Foundation Patient Assistance Program
For eligible patients with no medical insurance, or whose insurance does not cover therapy, and an annual household income at or below 500% of the federal poverty level, this program provides Gemzar at no cost.
Onivyde (irinotecan liposome
Drug company: Ipsen
Onivyde is a topoisomerase inhibitor used, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer whose disease has progressed after treatment with Gemzar.
Ipsen Cares offers 2 financial assistance programs for patients using Onivyde:
Onivyde Copay Program
Eligible patients with private insurance will pay $0 per order of Onivyde, with a maximum annual benefit of $20,000.
Ipsen Cares Patient Assistance Program
Uninsured patients who meet the income criteria may be eligible to receive Onivyde at no cost.
Tarceva (erlotinib) Tablets
Drug company: Genentech
Tarceva is a kinase inhibitor used, in combination with Gemzar, for the treatment of patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.
Genentech offers 2 financial assistance programs for patients using Tarceva:
Genentech BioOncology Co-pay Card
The program ensures a $25 copay for privately insured patients receiving Tarceva, with up to $25,000 provided annually, and has no income requirements for participation.
Genentech Access to Care Foundation
This foundation provides Tarceva free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Tarceva is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).
Table. Drugs Prescribed for Pancreatic Cancer
- Drug name (generic name)
- Drug company
- Patient support services
Drug name (generic name)
- Gemzar (gemcitabine)
- Eli Lilly
- Stage II or III pancreatic cancer that cannot be removed
Stage IV metastatic pancreatic cancer
Patient support services
- Lilly Cares Foundation Patient Assistance Program